Biophytis SA (BPTS): Price and Financial Metrics


Biophytis SA (BPTS): $0.46

-0.01 (-2.55%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add BPTS to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

BPTS Stock Price Chart Interactive Chart >

Price chart for BPTS

BPTS Price/Volume Stats

Current price $0.46 52-week high $5.91
Prev. close $0.48 52-week low $0.35
Day low $0.41 Volume 4,198
Day high $0.46 Avg. volume 20,950
50-day MA $0.45 Dividend yield N/A
200-day MA $0.93 Market Cap 9.29M

Biophytis SA (BPTS) Company Bio


Biophytis SA, a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients suffering from age-related diseases. Its therapeutics focuses on targeting and activating key biological resilience pathways that could protect against and counteract the effects of the multiple biological and environmental stresses that lead to age-related diseases. The company's lead drug candidate, Sarconeos (BIO101), is an orally administered small molecule in development for the treatment of neuromuscular diseases, including sarcopenia and Duchenne muscular dystrophy (DMD). Its second drug candidate, Macuneos (BIO201), is an orally administered small molecule in development for the treatment of retinal diseases, including dry ager elated macular degeneration (AMD) and Stargardt disease. Biophytis SA has a collaboration agreement with AFM-Telethon for the development of its Sarconeos (BIO101). The company was founded in 2006 and is headquartered in Paris, France.


BPTS Latest News Stream


Event/Time News Detail
Loading, please wait...

BPTS Latest Social Stream


Loading social stream, please wait...

View Full BPTS Social Stream

Latest BPTS News From Around the Web

Below are the latest news stories about BIOPHYTIS SA that investors may wish to consider to help them evaluate BPTS as an investment opportunity.

Biophytis: Judgment of the Paris Court of Appeal of 17 January 2023 in the Case Between Biophytis and Negma Group Ltd

Biophytis SA (NasdaqCM:BPTS)(Euronext Growth Paris:ALBPS) (the "Company" or "Biophytis"), a clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging, including severe respiratory failure in patients suffering from COVID-19, today announces that on the 17th of January 2023 the Paris Court of Appeal rendered a decision in the case between Biophytis and Negma Group Ltd

Yahoo | January 19, 2023

Biophytis To Take Appropriate Measures After Receiving Nasdaq Deficiency Notice

Biophytis SA (NasdaqCM:BPTS)(Euronext Growth Paris:ALBPS) (the "Company" or "Biophytis"), a clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging, including severe respiratory failure in patientssuffering from COVID-19, received a deficiency notice from The Nasdaq Stock Market, Inc. ("Nasdaq") stating that the Company has not filed its financial information for the

Yahoo | January 12, 2023

Biophytis announces its participation in two major investor conferences in January, in the United States and in France: the JP Morgan Healthcare Conference and the Invest Securities Biomed

Biophytis / Key word(s): Miscellaneous Biophytis announces its participation in two major investor conferences in January, in the United States and in France: the JP Morgan Healthcare Conference and the Invest Securities Biomed 05-Jan-2023 / 08:00 CET/CEST Biophytis announces

Wallstreet:Online | January 5, 2023

Biophytis Announces Its Participation in Two Major Investor Conferences in January, In the United States and In France: The JP Morgan Healthcare Conference and The Invest Securities Biomed

Biophytis SA (NasdaqCM:BPTS, Euronext Growth Paris:ALBPS), ("Biophytis" or the "company") a clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging, including severe respiratory failure in patients suffering from COVID-19, today announces its participation at the 41st JP Morgan Healthcare Conference, which will be held in San Francisco from the 9th to 12th of January

Yahoo | January 5, 2023

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

We're starting off the day with an overview of the biggest pre-market stock movers traders need to know about for Friday morning!

William White on InvestorPlace | December 2, 2022

Read More 'BPTS' Stories Here

BPTS Price Returns

1-mo 16.60%
3-mo -23.32%
6-mo -47.13%
1-year N/A
3-year N/A
5-year N/A
YTD 16.43%
2022 -92.60%
2021 N/A
2020 N/A
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6327 seconds.